Abstract:Abstract The mutation frequency of epidermal growth factor receptor (EGFR) is approximately 40% among Asian patients with NSCLC. Guidelines for the diagnosis and treatment of primary lung cancer in China recommended epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) as a first-line therapy for advanced NSCLC patients carrying EGFR mutation including exon 19 deletion (19Del) and L858R mutation on exon 21 (L858R). Although survival periods in clinical practice of EGFR-TKIs treatment have been getting longer, the patients with different subtype of EGFR mutations exhibited diverse drug response to EGFR-TKIs. The reasons why are still unclear. In this study, we performed whole genome and panel sequencing of 239 spatially distinct regions from 42 lung adenocarcinoma of Chinese patients, of which 14 patients carried EGFR 19del mutation (EGFR-19Del), 15 patients carried L858R mutation (EGFR-L858R) and 13 patients did not carry any of these two mutation types (Control). We found the intra-tumor heterogeneity (ITH) levels were significantly higher in EGFR-mutant patients compared with control (P<0.05). Average fraction of nonubiquitous mutation was 93.63%, 93.87% and 71.34% in EGFR-19Del, EGFR-L858R and Control, respectively. Remarkably, mutational process preferentially associated with different genes on different pathways were observed between two EGFR mutant subtypes, in which cell cycle related pathways were more likely to mutate in EGFR-L858R patients, while cell adhesion associated pathways were more susceptible to mutations in EGFR-19Del patients. Furthermore, two distinct evolutionary patterns were identified in EGFR-mutant patients based on whether TP53 mutations occurred simultaneously. In EGFR-mutant patients with stage I, the prognosis of patients with TP53 mutations was significantly worse than those without TP53 mutations. Meanwhile, we found that in the absence of TP53 mutations, more than 70% of EGFR-L858R patients showed multiple recurrent clonal driver mutations regardless of the stage of the patients. In contrast, EGFR-19Del patients only carried recurrent clonal driver mutation of EGFR in stage I, and began to accumulate other clonal driver mutations in later stage, which may indicate different evolutionary strategies underlying these two subtypes. These preliminary results suggested that intratumor genetic diversity provided a substrate for tumor adaptation and evolution in the subtype of EGFR mutation. It could provide genetic basis for diagnosis and prognosis in EGFR-TKIs therapeutic response and to guide stratification of lung cancer treatment and clinical research in future. Citation Format: Sitan Qiao, Xin Zhao, Xinlan Zhou, Yaxiong Zhang, Li Zhang, Kui Wu. Intratumor heterogeneity of non-small-cell lung cancer with EGFR mutations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2906.

Exploring the Cause of Survival Disparities in EGFR-mutated Lung Cancer Subtypes: Unraveling Distinctive Genomic and Phenotypic Features of 19del and L858R Mutation Subtypes

The Impact of EGFR Exon 19 Deletion Subtypes on Clinical Outcomes in Non-Small Cell Lung Cancer

Different Stories for Different EGFR Exon 19 Deletion Variants

Clinical Outcomes of EGFR-TKI Treatment and Genetic Heterogeneity in Lung Adenocarcinoma Patients with EGFR Mutations on Exons 19 and 21

Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations.

Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients.

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Abstract 2906: Intratumor heterogeneity of non-small-cell lung cancer with EGFR mutations

Non-small Cell Lung Cancer Patients with Ex19del or Exon 21 L858R Mutation: Distinct Mechanisms, Different Efficacies to Treatments

The Difference of Clinical Characteristics Between Patients with Exon 19 Deletion and Those with L858R Mutation in Nonsmall Cell Lung Cancer.

Different Efficacy of EGFR Tyrosine Kinase Inhibitors and Prognosis in Patients with Subtypes of EGFR-mutated Advanced Non-Small Cell Lung Cancer: a Meta-Analysis.

Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic Biomarkers

Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis.

Comparison of Therapeutic Effects of EGFR-tyrosine Kinase Inhibitors on 19del and L858R Mutations in Advanced Lung Adenocarcinoma and Effect on Cellular Immune Function

A Multicenter-Retrospective Study of Non-Small-cell Lung Carcinoma Harboring Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations: Different Subtypes of EGFR Exon 19 Deletion-Insertions Exhibit the Clinical Characteristics and Prognosis of Non-Small Cell Lung Carcinoma

The Comparison of Egfr-Tki Failure Modes and Subsequent Management Between Exon 19 Deletion and Exon 21 L858r Mutation in Advanced Non-Small-Cell Lung Cancer

Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma

Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival

Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations

Identification of tumor heterogeneity associated with KRAS/TP53 co-mutation status in lung adenocarcinoma based on single-cell RNA sequencing